莫努匹韦/莫诺拉韦效果怎么样？

How effective is Monupivir/Monoravir?

Monopivir/monoravir is highly effective and can reduce the risk of severe disease and death. It can be used to treat adult patients with mild or moderate new coronavirus infection who have tested positive for the new coronavirus (SARS-CoV-2) and are at higher risk of developing severe disease. Molnupiravir, also called monapiravir, was launched in the United States on December 23, 2021, and in China on December 30, 2022.

An international joint phase II/III trial (MOVe-OUT (002) trial) targeting SARS-CoV-2 infected patients over 18 years old, with the purpose of evaluating the effectiveness and safety of monupivir/molnupiravir, a placebo-controlled randomized double-blind parallel group comparison trial was implemented.

The primary assessment was the proportion of all randomly selected subjects who were hospitalized or died before day 29. Phase III: Molnupiravir 800 mg orally twice daily (every 12 hours). In the interim analysis as the main analysis, 775 cases were randomly assigned. The results of the main evaluation items when the follow-up until the 29th day of randomization (excluding Japanese subjects) were completed were 7.3% (28/385 cases) in the monupivir/molnupiravir 800 mg group and 14.1% (53/377 cases) in the placebo group. The difference between the proportions was -6.8%.

In addition, the results of the main evaluation items in the supplementary analysis of all cases of 1433 randomly assigned cases (including 8 Japanese subjects) were that 48/709 cases (6.8%) were hospitalized and 1/709 cases died (0.1%) in the monupivir/monabiravir 800 mg group, and 67/699 cases (9.6%) were hospitalized and 9/699 cases died in the placebo group ( 1.3%), unknown in 1/609 cases (0.1%). The incidence rate was 6.8% (48/709 cases) in the monupiravir/monabiravir 800mg group and 9.7% (68/699 cases) in the placebo group. The difference between the proportions between the groups was -3.0%.

Monupiravir/monabiravir (molnupiravir) is an oral ribonucleoside analog jointly developed by Merck and another biotechnology company called Ridgeback. It can inhibit the replication of a variety of RNA viruses, including the new coronavirus. It is recommended that patients take medication under the guidance of a doctor and receive symptomatic treatment.

Recommended related articles: